Palatin Technologies, Inc., established in Cranbury, New Jersey, in 1986, is a biopharmaceutical company focused on developing specialized, receptor-targeting therapeutics for various medical conditions within the United States. The firm's flagship product, Vyleesi, is an approved melanocortin receptor (MCr) agonist designed to treat hypoactive sexual desire disorder in premenopausal women. Beyond Vyleesi, Palatin's robust pipeline features several investigational compounds: Oral PL8177: A selective MC1r agonist peptide that has successfully completed Phase I clinical trials for the treatment of inflammatory bowel diseases.